Acadian Asset Management LLC Has $18.86 Million Holdings in Hologic, Inc. $HOLX

Acadian Asset Management LLC boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 333.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 289,500 shares of the medical equipment provider’s stock after purchasing an additional 222,654 shares during the period. Acadian Asset Management LLC owned about 0.13% of Hologic worth $18,863,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. Chung Wu Investment Group LLC bought a new stake in shares of Hologic in the 2nd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 273 shares during the period. Zions Bancorporation National Association UT bought a new stake in Hologic in the first quarter valued at approximately $34,000. Cromwell Holdings LLC increased its position in Hologic by 307.0% during the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 436 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Hologic during the 1st quarter valued at approximately $42,000. 94.73% of the stock is owned by institutional investors.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $74.60 on Wednesday. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $80.31. The stock’s 50 day moving average is $69.29 and its 200-day moving average is $65.44. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $16.59 billion, a price-to-earnings ratio of 30.95, a PEG ratio of 2.54 and a beta of 0.65.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same quarter in the previous year, the business posted $1.01 EPS. Hologic’s quarterly revenue was up 6.2% on a year-over-year basis. Sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HOLX has been the topic of a number of analyst reports. Royal Bank Of Canada raised shares of Hologic from a “sector perform” rating to an “outperform” rating and upped their price objective for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Evercore ISI set a $78.00 price target on shares of Hologic and gave the company an “outperform” rating in a research report on Tuesday, October 7th. BTIG Research reiterated a “neutral” rating on shares of Hologic in a report on Tuesday, October 21st. Argus boosted their price objective on Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Friday, September 19th. Finally, Wall Street Zen lowered Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and thirteen have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $79.77.

Insider Activity

In other news, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the sale, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.88% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.